Abstract #0044

Myocardial T2* Changes Periodically across the Cardiac Cycle and is Prolonged in Hypertrophic Cardiomyopathy: A 7.0 Tesla MRI Patient Study

Till Huelnhagen¹, Fabian Hezel¹, Teresa Serradas Duarte¹, Min-Chi Ku¹, Bert Flemming², Erdmann Seeliger², Marcel Prothmann³, Jeanette Schulz-Menger³, and Thoralf Niendorf^1,4,5

¹Berlin Ultrahigh Field Facility (B.U.F.F.), Max Delbrück Center for Molecular Medicine in the Helmholtz Association(MDC), Berlin, Germany, ²Institute for Physiology, Charité University Medicine, Berlin, Germany, ³Working Group on Cardiovascular Magnetic Resonance, Experimental and Clinical Research Center, a joint cooperation between the Charité Medical Faculty and the Max Delbrück Center for Molecular Medicine in the Helmholtz Association, Berlin, Germany, ⁴Experimental and Clinical Research Center, a joint cooperation between the, Charité Medical Faculty and the Max Delbrück Center for Molecular Medicine in the Helmholtz Association, Berlin, Germany, ⁵DZHK (German Centre for Cardiovascular Research), partner site Berlin, Berlin, Germany

Ultrahigh field MR (UHF-MR) enables temporally resolved myocardial T₂* mapping which benefits probing the myocardium at different physiological states. Myocardial BOLD contrast or T₂* are commonly regarded as surrogates for myocardial tissue oxygenation, but the factors influencing T₂* are manifold including cardiac macromorphology. Meaningful interpretation of myocardial T₂* could be beneficial for understanding cardiac (patho)physiology in vivo, but requires careful identification of influential factors and their contributions to T₂*. To this end, this study examines the relationship between myocardial T₂* and myocardial wall thickness and investigates it’s capability to distinguish between healthy myocardium and myocardium affected by hypertrophic cardiomyopathy (HCM).

This abstract and the presentation materials are available to members only; a login is required.

Join Here